Photo of Antoine E. Karnoub,

Antoine E. Karnoub

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 735-2082
Fax: (617) 735-2541


akarnoub@bidmc.harvard.edu

Antoine E. Karnoub

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

  • Assistant Professor, Pathology, Harvard Medical School
  • Assistant Professor, Pathology, Beth Israel Deaconess Medical Center

DF/HCC PROGRAM AFFILIATION

Research Abstract

Our laboratory at the Center for Life Sciences is interested in understanding the crosstalk that operates between the epithelial and the stromal compartments within breast tumors, with particular emphasis on how these interactions influence cancer metastasis. Our recent work indicated that bone-marrow-derived mesenchymal stem cells (MSCs) can home specifically to developing neoplasms where they integrate into the tumor stroma. Within this microenvironment, the tumor-associated MSCs initiate de novo secretion of chemokines which act on the cancer cells and promote their motility, invasion, and metastasis. Current efforts of our group aim to (1) decipher the nature of the cancer-derived systemic signals that affect the bone marrow and how such interactions mobilize MSCs and cause their recruitment to the tumor microenvironment; (2) characterize the nature of the heterotypic interactions that cause the activation of MSCs within the tumor stroma, and (3) elucidate the various mechanisms by which MSCs exert their pro-malignant functions.

Publications

Powered by Harvard Catalyst
  • Tasoglu S, Khoory JA, Tekin HC, Thomas C, Karnoub AE, Ghiran IC, Demirci U. Levitational Image Cytometry with Temporal Resolution. Adv. Mater. Weinheim 2015; 27:3901-8. PubMed
  • Cuiffo BG, Campagne A, Bell GW, Lembo A, Orso F, Lien EC, Bhasin MK, Raimo M, Hanson SE, Marusyk A, El-Ashry D, Hematti P, Polyak K, Mechta-Grigoriou F, Mariani O, Volinia S, Vincent-Salomon A, Taverna D, Karnoub AE. MSC-regulated microRNAs converge on the transcription factor FOXP2 and promote breast cancer metastasis. Cell Stem Cell 2014; 15:762-74. PubMed
  • Thomas C, Karnoub AE. Lysyl oxidase at the crossroads of mesenchymal stem cells and epithelial-mesenchymal transition. 2013; 4:376-7. PubMed
  • El-Haibi CP, Bell GW, Zhang J, Collmann AY, Wood D, Scherber CM, Csizmadia E, Mariani O, Zhu C, Campagne A, Toner M, Bhatia SN, Irimia D, Vincent-Salomon A, Karnoub AE. Critical role for lysyl oxidase in mesenchymal stem cell-driven breast cancer malignancy. Proc Natl Acad Sci U S A 2012; 109:17460-5. PubMed
  • El-Haibi CP, Karnoub AE. Mesenchymal stem cells in the pathogenesis and therapy of breast cancer. J Mammary Gland Biol Neoplasia 2010; 15:399-409. PubMed
  • Karnoub AE,Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 2008; 9:517-31. PubMed
  • Scheel C,Onder T,Karnoub A,Weinberg RA. Adaptation versus selection: the origins of metastatic behavior. Cancer Res 2007; 67:11476-9; discussion 11479-80. PubMed
  • Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polyak K, Tubo R, Weinberg RA. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449:557-63. PubMed
  • Ince TA, Richardson AL, Bell GW, Saitoh M, Godar S, Karnoub AE, Iglehart JD, Weinberg RA. Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell 2007; 12:160-70. PubMed
  • Karnoub AE,Weinberg RA. Chemokine networks and breast cancer metastasis. Breast Dis 2007; 26:75-85. PubMed